• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

michelle.yong@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-8692-4145

A/Prof Michelle Yong

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

93 Scholarly works
7 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring
    DOI: 10.1093/jac/dkag233
  • 2026

    Journal article

    Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies
    DOI: 10.1182/bloodadvances.2025019563
  • 2026

    Journal article

    Respiratory Viral Infections in SOT: Retrospective International Multicenter Study
    DOI: 10.1016/j.ajt.2026.05.124
  • 2026

    Journal article

    Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
    DOI: 10.1002/rmv.70142
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Transforming Infection Management in the Era of Emerging Cancer Therapies
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Applying Artificial Intelligence to a Learning Health Care System for Detection of Infections in Patients With Cancer
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Improving Patient Outcomes Through Implementation of Digital and Diagnostic Innovations for Infections in Cancer
Michelle Yong

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    The Diagnostic Approach to Pulmonary Complications in Allogeneic Hematopoietic Cell Transplantation: To Biopsy or Not?
    DOI: 10.1111/tid.70227
  • 2026

    Journal article

    Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients—PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT
    DOI: 10.1002/rmv.70135
  • 2026

    Journal article

    QuantiFERON-CMV Monitoring Post-Allogeneic Hematopoietic Stem Cell Transplantation Is Dynamic and Predictive of Immediate Cytomegalovirus Outcomes
    DOI: 10.1111/tid.70152
  • 2026

    Journal article

    Rhino-sino-orbital and/or central nervous system infections due to Lomentospora prolificans and Scedosporium spp. in onco-haematology patients
    DOI: 10.1093/mmy/myag016
  • 2026

    Journal article

    Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
    DOI: 10.1093/cid/ciaf409
  • 2026

    Journal article

    Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia
    DOI: 10.1080/10428194.2025.2599991

RECENT PROJECTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    Individualised Dose optiMisAtion of Ganciclovir in Immunocompromised Children (ID-MAGIC) Trial
  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224